MNTA: at least they believe MNTA will be the first ones approved. I'm not sure how they determine that MNTA will have a few months of exclusivity. I think most of this board believes that MNTA's competitors won't be approved until they achieve full characterization. Who knows when that happens. Maybe some of the analysts are erring on the conservative side.
Jbog et al: Sell-side analysts typically pick a target price out of thin air and then generate whatever assumptions about product approvals and cash flow are necessary to support their arbitrary target.
In this case, Leerink Swann’s most laughable assumption is the one that MNTA’s generic Copaxone will enjoy only three quarters as the sole FDA-approved generic. I guarantee that there will not be a second FDA-approved generic Copaxone from anyone during the next decade.
Market Data 
Markets 
AI
